Transcatheter therapy improves tricuspid regurgitation at 1 year
Click Here to Manage Email Alerts
At 1 year, 87% of patients who underwent transcatheter therapy for moderate to severe tricuspid regurgitation experienced a sustained regurgitation reduction of at least one grade, researchers reported at the virtual PCR e-Course.
Findings from the TRILUMINATE trial, which assessed the efficacy and safety of the transcatheter tricuspid valve repair system (TriClip, Abbott), also demonstrated low incidence of MACE and all-cause mortality and significant quality of life improvements.
For the single-arm, multicenter study, researchers assessed 1-year data of 85 patients at high surgical risk who underwent transcatheter tricuspid valve repair for moderate to severe tricuspid regurgitation.
Researchers observed that 87.1% of the trial participants achieved a regurgitation reduction of at least one grade at 1 year. Also, 70% of participants had moderate or less regurgitation at 1 year (P vs. baseline = .0001).
The incidence of MACE and all-cause mortality at 1 year was low (7.1% for both) and the rate of hospitalization was reduced 40% from 1 year before implantation to 1 year after implantation (P = .003), Philipp Lurz, MD, PhD, of the department of cardiology at Heart Center Leipzig at the University of Leipzig in Germany, said during a presentation.
Moreover, the rate of patients with NYHA class I or II improved from 31% at baseline to 83% at 1 year. Additionally, the average Kansas City Cardiomyopathy Questionnaire score among participants increased by an average of 20 points at 1 year (P < .0001), Lurz said.
“TriClip transcatheter therapy for patients with symptomatic moderate or greater tricuspid regurgitation results in durable tricuspid regurgitation reduction at 1 year with few major adverse events, and improvement in functional and clinical outcomes,” Lurz said during the presentation. “Transcatheter therapies for treatment of tricuspid regurgitation may offer a safe and effective alternative to surgery in this high-risk population.”
Collapse
Lurz P, et al. Mitral interventions – part 1. Presented at: PCR e-Course; June 25-27, 2020 (virtual meeting).
Click Here to Manage Email Alerts